PSNL

What one share of Personalis holds

Services – Medical Laboratories

Personalis develops, markets, and sells advanced cancer genomic testing services. Our testing services are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection.

Personalis’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.

Per-share figures
Sales$0.71
Profit−$1.10
Capex (buildings and equipment)$0.09
Free cash flow−$1.03
Cash and investments$0.88
Book value$2.21

Per share by fiscal year

YearSalesProfitCapexFree cashDividendsBook value
2017$3.10−$7.78$1.70−$1.61—−$30.50
2018$12.33−$6.49$2.56−$0.74—−$34.48
2019$3.62−$1.39$0.47−$1.47—$3.41
2020$2.29−$1.20$0.09−$1.34—$4.99
2021$1.95−$1.49$0.25−$1.87—$6.91
2022$1.42−$2.48$1.09−$2.63—$4.67
2023$1.53−$2.25$0.23−$1.39—$2.56
2024$1.43−$1.37$0.03−$0.79—$2.38
2025$0.78−$0.91$0.05−$0.89—$2.55

Common questions about Personalis

How much does one share of Personalis earn?

Over the last 12 months, Personalis lost $1.10 for each share on $0.71 of sales.

Does Personalis pay a dividend?

Personalis didn’t pay a dividend over the last 12 months, according to its SEC filings.

What is Personalis’s book value per share?

Personalis’s book value is $2.21 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.

How much cash and debt does each share of Personalis have?

Each share of Personalis has $0.88 of cash and investments, as of June 30, 2026.

What is Personalis’s free cash flow per share?

−$1.03 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.

Has Personalis bought back shares?

Personalis’s share count rose about 2844% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.

From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.